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EDITORIAL

Geriatric CKD: Value-Based Nephrology

E

ach nephrologist in the United States is now participating in a value-based purchasing (VBP) plan.
Nephrology patients, particularly geriatric individuals
with advanced CKD or ESRD represent the bulk of our
current and future VBP-based decision-making. Therefore, nephrologists must become more adept at valuebased decision-making, and these decisions must align
with the values of patients.
The “Medicare Hospital Spending by Claim” Web page
details comparative average hospital spending during a
speciﬁed interval of performance for a Medicare Spending
Per Beneﬁciary (MSPB) episode.1 The episode includes
Medicare Parts A and B claims paid for the period beginning 3 days before a hospitalization and up to 30 days
post-discharge. More speciﬁcally, a hospital’s MSPB
amount is determined by dividing the hospital’s average
MSPB by the national median MSPB amount for the nearly
3000 participating US hospitals. A hospital’s MSPB amount
represents its average price-standardized, risk-adjusted
spending for an MSPB episode. The price-standardization
normalizes payments by removing the effects of
geographic differences in payments and add-on payments
for indirect medical education and disproportionate share
hospitals. There is variation in the “spend” per hospital,
which is measured by diagnoses-related group reimbursement, and part of the variation is attributable to size (and
therefore risk) of the CKD and ESRD populations cared
for by a particular institution. Risk stratiﬁcation and adjustment for age uses the hierarchical condition categories and
ESRD status. Since an MSPB episode is a patient-level
event, adjustments are essentially case-mix adjusted and
are not included for all episodes collectively.
Because the MSPB measure is part of a VBP program, it
is evaluated based on results, not goals.2 Namely, achievement and improvement points are earned to offset the
1.75% standard penalty fee imposed by the VBP program
within the fabric of the Centers for Medicare and
Medicaid Services (CMS). Established in 2010 by the
Affordable Care Act, the VBP program was applied to
payments beginning in ﬁscal year 2013; incentive payments to participating hospitals are based on performance
on each measure and improvement on measures
compared to baseline status. The approved measures
and dimensions are grouped by speciﬁc domains of qual-

ity (Tables 1-3).2 Although ESRD is case-mix adjusted,
there are no explicit clinical processes of care measures
for ESRD. Arguably, the clinical process of care domain
and patient experience of care domain encompass what
is important to the ESRD patient (Table 1). One may argue
that the nephrologist and the patient should determine
what is most important to the patient. However, there is
no performance measure or quality metric for decisionmaking. Consequently, there should be some latitude
regarding ESRD metrics such as mortality ratios because
patient choice may be in direct opposition to metric performance. One example would be an incident maintenance hemodialysis patient with a hemodialysis catheter
older than 90 days who chooses not to undergo vascular
access surgery and subsequently develops a fatal central
line-associated bloodstream infection. The death negatively impacts the standardized mortality ratio of the hemodialysis unit. In this case, patient self-determinism
abridges CMS’ call for an abolition of dialysis catheters,
and the value-based hospital is penalized for it. CMS
would argue that the outcome domain for mortality of
ESRD patients remains exceedingly high. This patient’s
catheter-related death would be simply considered a failure on the nephrologist’s part by CMS. Notably, there
have been impressive reductions in ﬁrst- and secondyear death rates of, respectively, 14% and 16%, between
2003 and 2009.3 These improvements were driven by
reduced mortality from infections and cardiovascular disease. Hemodialysis catheter rates increased during this
period, following implementation of the Fistula First
Breakthrough Initiative.4 ESRD-related death from infections has decreased remarkably over the last 2 decades,
but mortality attributable to other causes has worsened
since 1999. Moreover, disturbingly high rates of allcause mortality persist in the early months of renal
replacement therapy (RRT) in the ESRD population,
particularly among the elderly. Succinctly, death in the
dialyzed is 10-fold greater than for similarly aged Medicare patients sans CKD. The worry is that invoking
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Table 1. Applicable Domains, Fiscal Year (FY) 2013 to 2015
FY

Applicable Domains

Table 2. Clinical Process of Care Measures, Fiscal Year (FY) 2013 to
2015
Measure ID

2013
2014

2015

Clinical process of care
Patient experience of care
Clinical process of care
Patient experience of care
Outcome
Clinical process of care
Patient experience of care
OutcomeEfficiency

AMI-7a
AMI-8a
HF-1
PN-3b

PN-6
Reproduced with permission from Department of Health and
Human Services, Centers for Medicare & Medicaid Services (2014,
November).2

patient-centeredness may affect value-based purchasing
in a perverse and negative way. On a population basis
in a value-based environment, one would argue that dialysis of the elderly represents an unfavorably very high
cost per patient.
A dialysis patient who is aged 65 years or older has
twice the mortality than a general population patient
who has either diabetes, cancer, congestive heart failure,
stroke, or acute myocardial infarction. Why are only
51% of dialysis patients and 82% of those undergoing preemptive kidney transplantation alive just 3 years after the
initiation of ESRD therapy? The answer has been hiding in
the open. Since 2005, the 3 most cited papers of “Advances
in Chronic Kidney Disease” in order are “The prevalence
of symptoms in end-stage renal disease: a systematic
review” by Murtagh, and colleagues in 2005,5 “Progression in chronic kidney disease” by Eddy in 2005,6 and
“Cognitive impairment in the aging dialysis and chronic
kidney disease populations: an occult burden” by Murray
and colleagues in 2008.7 A re-reading of these articles
along with “Cardiorenal syndrome in critical care: the
acute cardiorenal and renocardiac syndromes” by Cruz
in 20138 serves as a backdrop of this issue of Geriatric
Nephrology by Guest Editor, Samir Patel. In this issue, a
theme emerges: those with progressive CKD often have
subtle symptoms, including cognitive dysfunction and
depression, unrecognized by many health-care providers.
Acute kidney injury compounds this scenario in which
elderly patients with advanced CKD or who already are
on maintenance dialysis treatments become increasingly
and perilously frail, especially those with evolving cardiac
dysfunction: systolic, diastolic, and/or arrhythmogenic.
Another reason for premature death during RRT is found
in Pareto’s principle, the so-called “80–20 rule,” where 80%
of a problem results from just 20% of the mediators of the
problem. In ESRD, the probability density function is not
exactly 80 to 20, but mortality is greater than it should be
simply because nephrologists and/or patients have chosen
the “dialysis option” instead of the “no dialysis option” for
a variety of reasons.9 Some examples include the following:
(1) the patient has a serious disease, particularly in the critical care setting, and, if the patient is dialyzed, the patient
will “pull through”; (2) the patient is offered a menu of options for pre-end-of-life-care that includes dialysis, but the
patient and/or family are not informed that dialysis is likely

SCIP-Inf-1
SCIP-Inf-2
SCIP-Inf-3
SCIP-Inf-4

Measure Description
Fibrinolytic therapy received within 30 min of
hospital arrival
Primary PCI received within 90 min of hospital
arrival
Discharge instructions
Blood cultures performed in the emergency
department before initial antibiotic received
in hospital
Initial antibiotic selection for communityacquired pneumonia in immunocompetent
patients
Prophylactic antibiotic received within 1 h
before surgical incision
Prophylactic antibiotic selection for surgical
patients
Prophylactic antibiotics discontinued within
24 h after surgery end time
Cardiac surgery patients with controlled 6:00
a.m. postoperative serum glucose
Urinary catheter removal on postoperative day
1 or postoperative day 2

SCIP-Inf-9
(for FY
2014 – 2015
only)
SCIP-Card-2
Surgery patients on a beta-blocker before
arrival who received a beta-blocker during
the perioperative period
Surgery patients with recommended venous
SCIP-VTE-1
thromboembolism prophylaxis ordered
(for FY
2013-2014
only)
SCIP-VTE-2
Surgery patients who received appropriate
venous thromboembolism prophylaxis
within 24 h before surgery to 24 h after
surgery

Abbreviations: AMI, acute myocardial infarction; HF, heart failure;
PCI, percutaneous coronary intervention; PN, pneumonia; SCIP,
Surgical Care Improvement Project; VTE, venous thromboembolism.
Reproduced with permission from Department of Health and
Human Services, Centers for Medicare & Medicaid Services (2014,
November).2

permanent; (3) the patient and/or family will “never give
up hope”; (4) the nephrologist is discomforted by being
the last care provider to “pull the plug”; (5) familial, social,
and/or religious reasons; and (6) ﬁnancial reasons (possibly
immoral). Any of these 6 reasons may obscure more important discussions that better reﬂect patients’ wishes,
including symptoms, quality-of-life, and end-of-life preparation.
Regardless of the reason, our value-based imperative is
that we must do better. Otherwise, health-care costs
from ESRD will continue to escalate from their presently
disproportionate level of 7% of the greater than halfbillion dollars of total Medicare expenditures. Overall,
the goal is delivery of value-based care, that equates
with care of value to the patient. The ﬁnancial reward is
the corollary of the delivery of such care, not the driver.
Renal physicians must play a role in ﬁnding solutions to
this ﬁnancially unsustainable model of care by doing less
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Table 3. Outcome Measures, Fiscal Year (FY) 2014 to 2015
Measure ID

Measure Description

MORT-30-AMI

Acute myocardial infarction (AMI)
30-d mortality rate
MORT-30-HF
Heart failure (HF) 30-d mortality
rate
MORT-30-PN
Pneumonia (PN) 30-day mortality
rate
AHRQ PSI-90 composite Complication/patient safety for
(for FY 2015 only)
selected indicators (composite)
CLABSI (for FY 2015 only) Central line–associated blood
stream infection
Abbreviations: MORT-30-PN, Pneumonia (PN) 30-Day Mortality
Rate; MORT-30-AMI, Acute Myocardial Infarction (AMI) 30-Day Mortality Rate; MORT-30-HF, Heart failure (HF) 30-Day Mortality Rate;
CLABSI, central line associated blood stream infections; AHRQ
PSI-90, Agency for Healthcare Research and Quality, Primary Safety
Indicators #90.
Reproduced with permission from Department of Health and
Human Services, Centers for Medicare & Medicaid Services (2014,
November).2

and more. Because ESRD patients experience greater
cardiovascular morbidity and mortality, it would be
prudent to initiate quality improvement programs with
potential impact for CKD patients with known cardiovascular disease and before ESRD. First, kidney doctors must
partner better with heart doctors for patients with cardiorenal or renocardiac syndromes. Although the cardiorenal syndrome classiﬁcation of Ronco is nosologically
pleasing,10 the most important process of care is a collaboration between the cardiologist and nephrologist,
particularly regarding decisions involving anti-reninangiotensin-aldosterone therapies, diuretics, anticoagulation, and more recently dialytic therapy of heart failure
with left ventricular assist devices.
Patients who will not survive well on dialysis should not
be offered the opportunity to engage in a therapy
dangerous to them. Data from McIntyre11 have demonstrated substantial coronary circulatory compromise in
patients undergoing dialysis by cardiac positron emission
tomographic imaging. The coronary ischemia is often
completely asymptomatic, that is, until it becomes symptomatic. It is already acknowledged that there is an
increased frequency of heart failure, heart attacks, and
strokes in ESRD, and the degree of myocardial “stunning”
that takes place during hemodialysis is, in a word, stunning, and fosters further cardiac deterioration functionally
and histologically. Similar ﬁndings occur in the brain during dialysis. For ESRD patients with known cardiovascular disease, perhaps, a cooled dialysate may prevent
further heart and brain damage. The option of peritoneal
dialysis is certainly a good one and less costly in the long
run, ﬁnancially and probably medically, due to avoidance
of hemodialysis-induced myocardial stunning. Homebased hemodialysis, with its lesser but more frequent
ultraﬁltration volumes may abbreviate myocardial stunning, too, and deserves consideration.
Atrial ﬁbrillation and venous thromboembolism occur
more frequently in advanced CKD patients and ESRD patients than in the general population per data from the
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Chronic Renal Insufﬁciency Cohort study12,13 and
Dialysis Outcomes and Practice Patterns Study.14 Anticoagulation has not proven convincingly prophylactic in
the United States, and prospective trials are lacking in
terms of a protective effect of anticoagulation on the
reduction of either heart-related outcomes or strokes in
ESRD patients15; however, the Swedish Web-System for
Enhancement and Development of Evidence-Based Care
in Heart Disease Evaluated According to Recommended
Therapies analysis,16 which studied the inﬂuence of
CKD on warfarin therapy for atrial ﬁbrillation, is decidedly in favor of anticoagulation in CKD and ESRD patients. The percentage of time in the therapeutic range
for Swedish patients is astoundingly high at 80% or better,
too, and similar beneﬁts may be derived in US patients
given equal target attainment. Overall, decisions to implement oral anticoagulation therapy in geriatric CKD patients must be made only after comprehensive
evaluation of clinical context, particularly when depression or cognitive dysfunction is manifest.17
We have only just begun to recognize the inﬂuence of
frailty,18 depression, and cognitive dysfunction on the
morbidity and mortality of older ESRD patients. Any of
these factors may be additionally aggravated by disrupted
sleep, a common malady of ESRD patients, and to bad effect.19
There is no single solution or set of rules that deﬁnes
who to dialyze and which can be applied to geriatric patients. Preferably, a mortality risk stratiﬁcation process
should be applied individually to each patient before
devising and implementing a care plan.20 When several
of the aforementioned comorbidities are combined, it
may be the greater part of valor to withdraw dialysis or
not initiate it. This is a conversation that the nephrologist
should initiate with the patient earlier than later, or too
late. Some patients and/or their families may be affronted
by the notion of not offering all life-sustaining modalities.
However, gentle, well-intentioned conversations underscoring the balance between quality of life and lifespan
must be brought forth. Unfortunately, this is neither
done well nor comfortably by all nephrologists, as the
bulk of nephrologists have learned these skills informally
and by trial and error. Early training in this area must be
an imperative for all nephrology trainees so that competency in this vital communication skill can be obtained
by completion of nephrology fellowship training. A University of Pittsburgh program, NephroTalk is an ongoing
educational initiative that can improve the communication skills and ﬁnesse required for these difﬁcult patient–provider interactions and enhance patient-centered
kidney care.21 NephroTalk complements the VitalTalk
program that begins similar conversations in intensive
care units.
Truly, we must attempt to head off the health-care intensiﬁcation that occurs during initiation of chronic dialysis
in older, sicker geriatric patients with limited lifespans
and which is often futile.20 Many patients with more
advanced CKD and/or cardiac disease will develop an
episode of insufﬁciently resolving acute kidney injury
and begin a rapid decline in health with death as the
end point after only 6 to 9 months. Punctuation of the
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futility of this scenario comes in the form of inappropriate
resuscitative measures. To avoid these patient-harming
circumstances, advanced directives are necessary. In Germany, Driehorst and Keller22 found that structured interviewing of 200 patients admitted to a nephrology ﬂoor
led to the authoring of an advanced directive in 26% of
participants. However, more patients elected to forgo cardiopulmonary resuscitation than dialytic therapy. A
greater age of the patient was the variable of greatest
impact in this investigation. In a Spanish questionnaire
study of 135 chronically dialyzing participants, age (71.2
vs 62.2 years) was signiﬁcantly associated with denial of
cardiopulmonary resuscitation, ventilator use, tube feedings, or dialysis in the case of coma or persistent vegetative state, severe dementia, or terminal illness. Overall,
48% of participants denied these therapies. Thus, structured questioning and interviewing of maintenance dialysis patients regarding advanced directives is not only
patient-centered but may also avoid the unnecessary prolongation of life.
The Affordable Care Act has placed nephrologists in a
value-based clinical world, “again.” The implementation
of CMS’ Prospective Payment System did so ﬁrst. To
adroitly, effectively, and efﬁciently execute clinical processes of care in a cost-conscious manner, difﬁcult conversations and decisions must be made regarding the
treatment of geriatric patients with advanced CKD and
those already in receipt of RRT. This is not a rationing of
care but rather rational care. Quality of life counts, and
Smith and colleagues23 delineated this in their prospective
UK cohort of 36 high-risk and highly dependent patients
with kidney failure. Initiation of dialysis vs palliative
care was not statistically different in terms of median survival. Importantly, 65% of patients who underwent dialysis died in-hospital vs 27% in palliatively treated
patients, thereby establishing validation to what had previously been only suspicion. However, this study was of
small size and has not been replicated (or attempted) in
the United States. Here, following the lead of the Coalition
for Supportive Care of Kidney Patients established by Alvin W. Moss, we ﬁnd “like-minded people who care
deeply about the quality of compassionate, supportive
care for kidney patients” and whose stated goal is to
“create culture change that transforms the treatment of
persons with kidney disease, putting every patient at
the center and integrating palliative principles and practices throughout the care continuum.” For the less wellinitiated, excellent guidance on how to proceed on the
palliative path has been rendered by Grubbs and colleagues24 and the Renal Physicians Association.25 Both
serve as processing frameworks for ESRD patients who,
after meaningful conversations with their nephrologist,
choose palliative care over RRT.
The nephrology community that cares for patients who
may require RRT must remain mindful of their patients’
wishes and inform them of all options and then, the best
ones. Payers must appreciate that this is substantive,
non-procedural work of which payment is far less than
the enterprise of an initiation of RRT that may not end
well. To this end, on October 30, 2015, CMS established
Medicare coverage for 2 Current Procedural Terminol-

ogy codes for advance care planning, effective for use
for services provided on or after January 1, 2016—a
Pyrrhic victory. Notably, it has taken decades to unconvince ourselves that patients with advanced cognitive
dysfunction or dementia should have feeding tubes implanted,26 and the same is true for patients who are not
improving their quality of life with RRT. In summary,
care of the geriatric CKD patient requires more than
the average skills of the nephrologist. Time and timing
are of the essence for this vulnerable population.
Becoming a value-based nephrologist requires artfulness
in the application of “soft skills” as much as an appreciation of an evidence-based approach. For those who
wish to undertake the care of geriatric CKD patients,
there is opportunity to enhance their overall patient
experience. Heed the words of Cohen and colleagues:
“The ﬁeld of nephrology is shifting from an exclusive
focus on increasing survival to one that provides greater
attention to quality of life. There is an opportunity to
integrate many of the advances of palliative medicine
into the comprehensive treatment of these patients.”27
“It was a good death.”

—J.H.
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